VAYA Pharma, a division of Enzymotec Ltd. (NASDAQ: ENZY) and innovator of lipid-based medical foods, today announced the relocation of its global headquarters from the University of Maryland BioPark to new offices located at 10480 Little Patuxent Parkway, Suite 900 in Columbia, Md. The move signals VAYA Pharma’s rapid growth as it graduates from the University of Maryland BioPark to larger corporate offices in the state.

With more than 70 employees in the U.S., including 15 employees at its Baltimore office, the company has grown more than 30% annually over the last three years.

“Our strategic location within the University of Maryland BioPark gave us access to a diverse group of biotech leaders and resources, which really helped propel our growth and drive success,” said Rob Crim, CEO of VAYA Pharma. “We are excited about the move to Columbia, as we are committed to staying in Maryland, which is a hotbed for biotech and life science innovation.”

VAYA Pharma is a subsidiary of Enzymotec Ltd., an Israeli-based medical food manufacturer. In 2016, Governor Hogan met with Enzymotec executives during a trade mission to Israel, which sought to promote Maryland as a center for Israeli businesses seeking to have a U.S. presence.

“Maryland and Israel share many strengths and similarities, as thriving centers for biotechnology and innovation,” said Barry Bogage, executive director of the Maryland/Israel Development Center, the organizer of Hogan’s trade mission. “We’re thrilled that an Israeli-owned company has chosen Maryland for its U.S. headquarters and we look forward to supporting the growth of VAYA Pharma and its innovative medical foods products.”   

For more information, visit www.vayapharma.com.